Efficacy and safety of telithromycin 800 mg once daily for 7 days in community-acquired pneumonia: an open-label, multicenter study

BACKGROUND: Community-acquired pneumonia (CAP) remains a major cause of morbidity and mortality throughout the world. Telithromycin (a new ketolide) has shown good in vitro activity against the key causative pathogens of CAP, including S pneumoniae resistant to penicillin and/or macrolides. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Fogarty, Charles M, Patel, Tushar C, Dunbar, Lala M, Leroy, Bruno P
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1177948/
https://www.ncbi.nlm.nih.gov/pubmed/15927060
http://dx.doi.org/10.1186/1471-2334-5-43

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1177948/
https://www.ncbi.nlm.nih.gov/pubmed/15927060
http://dx.doi.org/10.1186/1471-2334-5-43

Ejemplares similares